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Activation of mitochondrial ATP-sensitive
potassium channels improves rotenone-related
motor and neurochemical alterations in rats
Yong Yang1,2, Xing Liu2, Yan Long2, Fang Wang2, Jian-Hua Ding2, Su-Yi Liu2,
Ye-Hong Sun2, Hong-Hong Yao2, Hai Wang3, Jie Wu2,4 and Gang Hu1,2
1 Laboratory of Reproductive Medicine, 2 Department of Pharmacology & Neurobiology, Nanjing Medical University, Nanjing
210029, Jiangsu, PR China
3 Beijing Institute of Pharmacology and Toxicology, Beijing 100850, PR China
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Abstract
Our previous studies revealed that activation of mitochondrial ATP-sensitive potassium channels exerted
protective effects on rotenone-treated rats and cultured cells. The aim of the present study is to examine
the potential therapeutic effects of iptakalim, an ATP-sensitive potassium-channel opener, and diazoxide,
a selective mitochondrial ATP-sensitive potassium-channel opener, on Parkinsonian symptoms in rats
induced by rotenone. Rats were treated with rotenone (2.5 mg/kg s.c.) daily for 4 wk. This treatment
caused a depletion of dopamine in the striatum and substantia nigra. Behaviourally, rotenone-infused
rats exhibit Parkinsonian symptoms. Catalepsy was estimated by a 9-cm bar test. Treatment with L-dopa
(10 mg/kg.d p.o.), iptakalim (0.75, 1.5, 3.0 mg/kg.d p.o.) and diazoxide (3.0 mg/kg.d p.o.) for 2 wk
improved behavioural dysfunction and elevated dopamine contents in the striatum and substantia
nigra of rotenone-treated rats. Studies also found that iptakalim and diazoxide could reduce the enzymic
activities and mRNA levels of inducible nitric oxide synthase elicited by chronic administration of
rotenone. All neurorestorative effects by both iptakalim and diazoxide were abolished by 5-hydroxy-
decanoate, a selective mitochondrial ATP-sensitive potassium-channel blocker. Collectively, the data
suggested that mitochondrial ATP-sensitive potassium channels play a key role in improving both
Parkinsonian symptoms and neurochemistry alterations of rotenonemodel rats, and selective activation of
mitochondrial ATP-sensitive potassium channels may provide a new therapeutic strategy for treatment
of early Parkinson’s disease.
Received 27 October 2004 ; Reviewed 19 January 2005 ; Revised 31 January 2005 ; Accepted 9 February 2005
Key words : Diazoxide, iptakalim, mitochondrial ATP-sensitive potassium channels (mito-KATP),
Parkinson’s disease, rotenone.
Introduction
Parkinson’s disease (PD) is a common neurodegen-
erative disorder of unknown aetiology, the cardinal
features of which include tremor, rigidity, slowness
of movement and postural instability. Its patholog-
ical hallmarks are loss of dopaminergic neurons in
the substantia nigra pars compacta (SNpc) and the
presence of neuronal proteinaceous cytoplasmic in-
clusions, commonly known as Lewy bodies (Fahn and
Przedborski, 2000). Neurodegeneration of the SNpc
results in a dramatic decrease in dopamine (DA) con-
tent in the corpus striatum. Thus far, both genetic
mutations and environmental factors have been
considered as contributors to certain forms of this
disorder (Steece-Collier et al., 2002). Recent evidence
suggests that mitochondrial damage, particularly
to the respiratory chain of complex I (CXI, NADH/
ubiquinone oxidoreductase) resulting in oxidative
and nitrative stress, underlies the pathology of PD
(Dawson and Dawson, 2003 ; Greenamyre et al., 1999 ;
Schapira et al., 1990 ; Zhang, et al., 2000). Rotenone,
an inhibitor of mitochondrial NADH dehydrogenase,
has been widely used as an herbicide and fish de-
stroyer in reservoirs (Gutman et al., 1970 ; Horgan
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et al., 1968). A majority of studies employing rotenone
have focused on the ability of this toxin to induce
neuropathological effects in rats which are reminiscent
of those seen in PD: loss of dopaminergic terminals
in the striatum and the formation of Lewy body-like
inclusions in the substantia nigra (Alam and Schmidt,
2002 ; Betarbet et al., 2000 ; Sherer et al., 2003). Be-
haviourally, rotenone-infused rats exhibit reduced
mobility, flexed posture and, in some cases, rigidity
(Sherer et al., 2003) and catalepsy (Alam and Schmidt,
2002). Therefore, the rotenone-treated rat is a suitable
model to investigate new possible therapeutic targets
for PD.
Current understanding of basal ganglia circuitry
and the pathophysiology of PD has led to major break-
throughs in the treatment of this debilitating move-
ment disorder. Unfortunately, there are significant
problems with the current available pharmacological
therapies, which mainly focus on DA replacement
(L-3-4-dihydroxyphenylalanine ; L-dopa) or dopami-
nergic agonists. There are no successful therapies to
prevent cell death (‘neuroprotection’) and/or restore
damaged neurons to a normal state (‘neurorestora-
tion’ ; Dawson and Dawson, 2002 ; Meissner et al.,
2004). Consequently, considerable amounts of efforts
have focused on developing novel targets for the
treatment of PD.
ATP-sensitive potassium channels are located in
various parts of the cells, including the surface of the
plasmalemmal membrane (sKATP) and the inner mito-
chondrial membrane (mito-KATP, Busija et al., 2004;
Inoue et al., 1991). Although the precise protein com-
position of mito-KATP channels has not been estab-
lished, a distinct pharmacology of mito-KATP channels
has been established: they are selectively activated
by low concentrations of diazoxide (Dia) and blocked
by 5-hydroxydecanoate (5-HD; Ghosh et al., 2000;
Sato et al., 2000). Recently, some candidates of
mito-KATP channel proteins have been identified.
Immunopositive colloidal gold particleswere scattered
over the mitochondria, suggesting that Kir6.1 was
located on the inner membrane (Suzuki et al., 1997).
Bajgar et al. (2001) have isolated and purified a novel
mito-KATP channel protein from rat brain mitochon-
dria that exhibits ligand-binding properties similar to
those of heart mito-KATP channels. Accumulating data
have indicated that the amount of mito-KATP channels
located in brain cells is at least 6-fold higher than in
heart cells. There is also abundant evidence linking
the activation of mito-KATP channels to protection
against neuronal injury or apoptosis, which concep-
tually supports the view that the protective effects
triggered by activation of mito-KATP channels may
potentially and feasibly serve therapeutic roles for
PD (Horiguchi et al., 2003 ; Kis et al., 2003 ; Liu et al.,
2002 ; Rajapakse et al., 2002; Tai et al., 2003 ; Teshima
et al., 2003).
Iptakalim (Ipt) is a KATP channel opener used
as an antihypertensive drug (Wang, 1998, 2003).
Interestingly, our recent research has revealed that
Ipt could open mito-KATP channels thereby exhibiting
significant neuroprotection – not only in promoting
behavioural recovery but also in protecting neurons
against necrosis and apoptosis in different animal
models of stroke and rotenone-induced Parkinsonian
symptoms in rats, as well as cell cultures (Wang et al.,
2004 ; Yang et al., 2004). The aims of this study are
to study the possible treatment of Ipt and Dia on
Parkinsonian symptoms in rats induced by rotenone
and investigate the neurorestorative role(s) of mito-
KATP channel openers on neurodegenerative diseases.
Behavioural measures sensitive to varying degrees
of catalepsy were used (Schallert et al., 2000). DA
and related neurotransmitters in the striatum and
substantia nigra tissues were measured by high-
performance liquid chromatography with electro-
chemical detection (HPLC-ECD). The activities and
mRNA levels of nitric oxide synthase (NOS) were
measured as described below.
Methods
Materials
Rotenone, Dia, L-dopa and all the solvents for HPLC-
ECD were obtained from Sigma (St. Louis, MO, USA).
Sodium 5-HD was purchased from Valeant Phar-
maceuticals International (Costa Mesa, CA, USA). All
PCR primers were purchased from Sangon (Sanghai,
China). All reagents for RT–PCR were purchased from
Promega (Madison, WI, USA).
Animals and treatment
A total of 150 adult male Sprague–Dawley rats
(Shanghai, China) aged 7 wk were chosen for the
experiments. At the beginning of the experiments,
they weighed 220–240 g. They were kept under
standard laboratory conditions (six housed per large
animal cage) : free access to standard laboratory
food and tap water, constant room temperature of
22 xC, 50–60% humidity with a natural day–night
cycle, etc. All experiments were carried out according
to the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (publication no. 85-23,
revised 1985) and approved by IACUC (Institutional
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Animal Care and Use Committee of Nanjing Medical
University).
Dimethyl sulphoxide (DMSO)/PEG (1/1) was used
as vehicle for rotenone. Dia was dissolved in 100%
DMSO as vehicle and diluted with sterile saline to
a concentration of 1 mg/ml (0.2% DMSO) for admin-
istration to rats. Ipt and 5-HD, a selective mito-KATP
channel blocker, was dissolved in saline. L-dopa
methyl ester was dissolved in physiological saline
containing 0.2% ascorbic acid. Benserazide hydro-
chloride (Sigma; 1/4 dose of L-dopa), a peripheral
dopa-decarboxylase inhibitor, was also dissolved in
physiological saline.
Rats were injected subcutaneously (s.c.) with
2.5 mg/kg rotenone/d at 08 :00, 14:00 and 20:00 hours
respectively, for 28 d. The injection volume was
0.1 ml/100 g body weight. Control rats were treated
with an equal volume of rotenone solvent. A catalepsy
test was used to screen the PD model 4 wk after
systemic rotenone treatment. The rats were placed
with both forepaws on bars 9 cm above and parallel
from the base and were in a half-rearing position.
Latency time of the removal of the paw was recorded.
The criterion for a successful model was defined as
latency time o15 s. Sixty-four successful PD model
rats were selected and divided into eight groups
according to the latency time. The number of rats
in every group was eight. The mean of latency time
of each group remains proximate. The groups were
outlined below.
Group A: Vehicle control rats+0.2% DMSO in saline
[per oral (p.o.)] ;
Group B: Rotenone model rats+0.2% DMSO in saline
(p.o.) ;
Group C: Rotenone model rats+0.75 mg/kg . d Ipt
(p.o.) ;
Group D: Rotenone model rats+1.5 mg/kg . d Ipt
(p.o.) ;
Group E: Rotenone model rats+3.0 mg/kg . d Ipt
(p.o.) ;
Group F: Rotenone model rats+10 mg/kg . d L-dopa
(p.o.) ;
Group G: Rotenone model rats+3.0 mg/kg . d Dia
(p.o.) ;
Group H: Rotenone model rats+5.0 5-HD mg/kg . d
(p.o.)+3.0 mg/kg . d Ipt (p.o.) ;
Group I : Rotenone model rats+5.0 5-HD mg/kg . d
(p.o.)+3.0 mg/kg . d Dia (p.o.).
On day 36, Ipt, Dia or L-dopa combined with benser-
azide hydrochloride (1/4 dose of L-dopa) was ad-
ministered by gavage (p.o.) on a daily basis for 14 d.
Benserazide hydrochloride was administered 30 min
before treatment with L-dopa. The volume was 1 ml/
100 g body weight for all drugs. Behavioural tests
were performed 60 min after drugs administration.
Behavioural tests
The catalepsy test was chosen for the assessment of
the effects of drugs on rotenone-induced Parkinsonian
symptoms and was performed as illustrated in
Figure 1. All experiments were arranged between
09:00 and 14:00 hours, always in the same context
and at standard conditions. The maximum prolonged
latency time was 180 s (Alam and Schmidt, 2002,
2004).
Neurochemistry procedure
One week after the behavioural test, animals were
sacrificed and their brains were rapidly removed
(within 25–40 s) and placed in ice-chilled 0.9% NaCl
solution for 1 min. Tissue samples of the striatum
and substantia nigra were taken bilaterally and
immediately weighed and stored in liquid nitrogen
until assay.
Model screenRotenone
2.5 mg/kg.d s.c.
Day 1 28 29 36
Pre Aft
Behavioural tests
38 40 42 46 49
Drug treatment (daily)
Figure 1. Experimental design.
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Frozen tissue was sonicated in 0.1 M HClO4 con-
taining 0.5% Na2EDTA and 0.1% Na2SB3OB5 (30 ml
for every 10 mg tissue) and centrifuged at 12000 g for
20 min at 4 xC. The supernatant was centrifuged
again for another 10 min under the same conditions.
Sample supernatant was analysed directly for DA,
dihydroxyphenylacetic acid (DOPAC), homovanillic
acid (HVA), noradrenalin (NE), serotonin (5-HT) and
5-hydroxyindoleacetic acid (5-HIAA, 5-HT’s meta-
bolite) by reverse-phase HPLC coupled to an electro-
chemical detector (HPLC-ECD).
HPLC-ECD for monoamine neurotransmitters con-
sisted of BAS LC-4C, a reversed-phase C18 column
(UltrasphereODS4.6 mmr250 mm,5 mm;GLSciences
Inc., Tokyo, Japan), chromograph interface DA-5, and
solvent delivery system. The mobile phase consisted
of 0.1 M citrate, 75 mM Na2HPO4, 0.1 mM EDTA, 1.0 mM
1-heptanesulphonic acid, 10% methanol (pH 3.9).
Chromatograms were analysed with the aid of a
chromatographic data system (BAS; Yang et al., 2004).
Sample results were expressed as pg/mg of tissue.
NOS activity assay
Nitric oxide (NO) is synthesized from L-arginine by
the enzyme NOS (Knowles and Moncada, 1994).
Three main types of the synthase (NOS) enzyme are
associated with differing roles : endothelial NOS
(eNOS), which is expressed in endothelial cells ; in-
ducible NOS (iNOS), which is not expressed in the
CNS except in the inflammatory state after lipopoly-
saccharide or cytokine induction in glial cells ; and
neuronal NOS (nNOS), which is localized in neurons
(Heneka and Feinstein, 2001 ; Vincent and Kimura,
1992). In this study, NOS activities in the striatum and
substantia nigra were determined as described pre-
viously (Zhu et al., 2002). Briefly, samples of striatum
and substantia nigra were homogenized and NOS
activities in supernatants were measured spectro-
photometrically using a commercially available kit
(Juli Bioengineering Co., Nanjing, China). Ca2+-
independent NOS activity was measured by adding
EGTA (3 mM) to chelate-free Ca2+ from the reaction
mixture. Ca2+-dependent NOS activity was computed
by subtracting Ca2+-independent NOS activity
from total NOS activity. NOS activity is expressed
as picomoles of NO formed in 1 min by 1 mg of
protein. Calcium-dependent activity in cytosolic
samples is considered to representnNOSbecauseeNOS
is primarily associated with membranes (Johansson
et al., 2002). Protein concentration in the samples
was determined by the Bradford method (Bradford,
1976).
RNA extraction and reverse transcription–PCR
(RT–PCR)
Total RNAwas extracted from the samples of striatum
and substantia nigra using Trizol reagent according to
the manufacturer’s instructions (Sigma). The PCR
primers were designed to amplify the iNOS product
(230 bp). The composition of iNOS was selected from
the sequence (GenBank accession no: NM_012611).
The sense primer for iNOS was 5k-CTGCATGGAA-
CAGTATAAGGCAAAC-3k, and the antisense primer
was 5k-CAGACAGTTTCTGGTCGATGTCATGA-3k.
For assessment of the cDNA quality, a pair of GAPDH
primers was designed (GenBank accession no:
BC059110). The forward primer was 5k-TGGTGCC-
AAAAGGGTCATCTCC-3k and the reverse primer
was 5k-GCCAGCCCCAGCATCAAAGGTG -3k to
amplify a 559-bp product. PCR conditions for iNOS
were 35 cycles of denaturation at 95 xC for 45 s,
annealing at 63 xC for 45 s, and extension at 72 xC for
45 s. PCR conditions for GAPDH were 25 cycles of
denaturation at 95 xC for 45 s, annealing at 60 xC for
45 s, and extension at 72 xC for 45 s. Following the
last cycle, the final extension was performed at 72 xC
for 10 min for all PCR analyses. The amplified pro-
ducts were separated by electrophoresis in 1rTris–
acetate EDTA buffer with a 2% agarose gel containing
0.1 mg/ml of ethidium bromide (4 ml). The DNA bands
were visualized and analysed by JD-801 Gel Electro-
phoresis Image analytic system (Jiangsu, China).
The ratio of NOS mRNA and GAPDH mRNA was
calculated.
Statistical analysis
All data are expressed as mean ¡ S.E.M. Statistical
analysis was carried out using STATA 7.0 software (Stata
Corporation, College Station, TX, USA). The catalepsy
data of different groups were compared by the non-
parametric (multifactorial Kruskal–Wallis test, rank
transformation and one-way ANOVA followed by
Scheffe´ multiple-comparison test). The neurochemical
data were analysed by one-way ANOVA followed by
Newman–Keuls test. A p value<0.05 and p<0.01 was
taken as levels of statistical significance (Alam and
Schmidt, 2004).
Results
Behavioural tests
Catalepsy
Rotenone-treated animals showed prolonged latency
time compared to the vehicle-treated control group
54 Y. Yang et al.
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using the bar test. On day 1 of treatment with L-dopa,
there was no significant difference in the descent
latency compared to model rats with saline (group B).
The L-dopa administration group (group F) showed a
significant reversal in the descent latency compared
to the model group (group B) on days 38, 40, 42, 46,
49 (p<0.01, Table 1). PD model rats treated with Ipt
and Dia exhibited a significant decrease in latency
time similar to rats administered L-dopa, especially
in group D (Ipt 1.5 mg/kg . d p.o.) and group G (Dia
3.0 mg/kg . d p.o.), which was more significant than
that observed in group C (Ipt 0.75 mg/kg . d p.o.)
and group E (Ipt 3.0 mg/kg . d p.o.). In groups H and I,
the latency time of the rats pre-administered 5-HD
(5.0 mg/kg . d p.o.), a selective mito-KATP channel
blocker, showed no significant difference compared
with the model rats (group B, p>0.05).
Neurochemical changes
In the second experiment, levels of DA and its meta-
bolites (DOPAC and HVA), NE, 5-HT and its metab-
olite (5-HIAA) were measured in the substantia nigra
(Table 2) and striatum for each group of animals
Table 1. Effects of iptakalim, diazoxide and L-dopa on catalepsy [latency time (s)] of rotenone-treated rats
Groups (mg/kg)
Day
36-Pre 36-Aft 38 40 42 46 49
(A) Veh+Sal 1.7¡0.6 1.9¡0.7 2.3¡0.5 1.8¡0.6 1.8¡0.6 1.9¡0.5 2.0¡0.4
(B) Rot+Sal 28.5¡6.3 29.2¡9.5 34.1¡10.6 41.3¡18.0 39.6¡17.5 45.4¡15.0 46.5¡10.3
(C) Rot+0.75 Ipt 27.3¡5.3 28.3¡6.9 25.6¡6.8 21.4¡8.1## 20.4¡8.6## 22.9¡6.1## 22.6¡6.2##
(D) Rot+1.5 Ipt 28.0¡6.1 27.4¡3.5 17.8¡5.0# 13.8¡3.5## 12.0¡4.4## 13.0¡4.6## 15.9¡4.2##
(E) Rot+3.0 Ipt 29.3¡4.5 28.4¡7.8 25.3¡8.0 19.4¡5.3## 20.2¡6.5## 21.3¡6.2## 22.1¡6.0##
(F) Rot+10 L-dopa 27.4¡6.1 28.1¡10.3 13.8¡3.1## 12.0¡4.1## 11.4¡3.7## 14.6¡4.7## 17.8¡4.7##
(G) Rot+3.0 Dia 28.6¡6.7 26.6¡8.8 22.5¡7.9 18.9¡5.1## 17.9¡6.3## 19.8¡4.6## 20.9¡2.5##
(H) Rot+5.0 5-HD+3.0 Ipt 28.0¡8.2 29.3¡7.8 33.5¡9.6 33.6¡8.6+ 41¡9.5++ 41.6¡11.9+ 42.8¡10.9++
(I) Rot+5.0 5-HD+3.0 Dia 27.3¡5.5 28.7¡6.6 31.6¡8.5 36.1¡6.7## 39.8¡6.9## 37.9¡12.6# 40.3¡11.4#
Veh, Vehicle ; Sal, saline ; Rot, rotenone ; Ipt, iptakalim; Dia, diazoxide ; 5-HD, 5-hydroxydecanoate.
Successful Parkinson’s disease model rats were grouped and treated with 0.2% DMSO in saline, L-dopa (10.0 mg/kg . d p.o.), Ipt
(0.75, 1.5, 3.0 mg/kg . d p.o.) or Dia (3.0 mg/kg . d p.o.) with or without 5-HD (3.0 mg/kg.d, p.o.) respectively. Catalepsy tests
were performed 60 min after drug administration. Data are expressed as latency time of the removal of the paw (s) and given as
mean¡ S.E.M. (n=8). p represents statistical analysis : # p<0.05, ## p<0.01 vs. group B; +p<0.05, ++p<0.01 vs. group E and
# p<0.05, ## p<0.01 vs. group G (multifactorial Kruskal–Wallis test, rank transformation and one-way ANOVA followed by
Scheffe´ multiple comparison test).
Table 2. Effects of iptakalim, diazoxide and L-dopa on monoamine levels in the striatum of rotenone-treated rats
Groups (mg/kg) DA DOPAC HVA NE 5-HT 5-HIAA
(A) Veh+Sal 7141¡422 1673¡314 429¡73 3141¡330 468¡66 434¡55
(B) Rot+Sal 2920¡347** 1294¡225* 333¡52** 1776¡446** 239¡57** 275¡40**
(C) Rot+0.75 Ipt 4505¡641**## 1640¡294# 403¡71# 2564¡538*## 395¡64## 436¡69##
(D) Rot+1.5 Ipt 6745¡574## 1602¡285# 414¡69# 3110¡398## 410¡70## 439¡71##
(E) Rot+3.0 Ipt 7014¡870## 1729¡219## 400¡63# 3004¡546## 345¡70## 420¡74##
(F) Rot+10 L-dopa 7462¡794## 2318¡664*## 472¡108 ## 2857¡315## 293¡70** 328¡72
(G) Rot+3.0 Dia 6104¡724**## 1660¡360# 424¡69 ## 2755¡347## 411¡48## 439¡66##
(H) Rot+5.0 5-HD+3.0 Ipt 3586¡476**##++ 1274¡211**++ 345¡40*+ 1915¡167**++ 262¡39**+ 308¡38**+
(I) Rot+5.0 5-HD+3.0 Dia 3324¡451**## 1230¡251**# 337¡68*## 2028¡270**## 278¡37**## 317¡35**##
DA, Dopamine; DOPAC, dihydroxyphenylacetic acid ; HVA, homovanillic acid ; NE, noradrenalin ; 5-HT, serotonin ; 5-HIAA,
5-hydroxyindoleacetic acid ; Veh, vehicle ; Sal, saline ; Rot, rotenone ; Ipt, iptakalim; Dia, diazoxide ; 5-HD, 5-hydroxydecanoate.
Data are expressed as picograms per milligram (pg/mg) of fresh brain weight and given as mean¡S.E.M. (n=8). p represents
statistical analysis : * p<0.05, ** p<0.01 vs. group A; # p<0.05, ## p<0.01 vs. group B; +p<0.05, ++p<0.01 vs. group E;
# p<0.05, ## p<0.01 vs. group G (one-way ANOVA followed by the Newman–Keuls test).
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(Table 3). We found that chronic rotenone adminis-
tration reduced DA content of the striatum byy60%,
NE content by nearly 40%, and 5-HT and its metab-
olite (5-HIAA) by almost 25%, similar to the reduction
observed in DA metabolites (such as DOPAC, and
the final metabolite, HVA). L-dopa administration
(10 mg/kg.d p.o.) elevated the levels of DA and NE,
but had no effect on the levels of 5-HT and 5-HIAA.
Ipt (0.75 mg/kg.d p.o.) significantly elevated the
content of DA in the striatum and substantia nigra
compared to the model rats (group B). In groups D, E,
F and G, neurotransmitter levels of rotenone model
rats treated with Ipt (1.5, 3.0 mg/kg . d p.o.), Dia
(3.0 mg/kg . d p.o.) and L-dopa (10 mg/kg . d p.o.)
for 2 wk showed no significant differences with
the vehicle control rats (group A). In groups H and I,
5-HD (5.0 mg/kg . d p.o.) abolished the effects of Ipt
and Dia.
Identification of NOS activities and mRNA levels
in the striatum and substantia nigra
In this study, we measured NOS activities and mRNA
levels in both the striatum and substantia nigra. The
iNOS activities and mRNA levels in rotenone-treated
rats were several times higher compared to vehicle
control rats (Figures 2 and 3). Except for group C,
there was no significant difference between the vehicle
control group and Ipt- or Dia-treated groups. Ipt
(0.75 mg/kg . d, p.o.) also significantly reduced iNOS
activities and mRNA levels in group C compared to
group B (model rats). 5-HD abolished the effects of
Ipt and Dia. L-dopa had no effect on NOS activity and
mRNA levels in both brain regions.
nNOS activities of the striatum and substantia nigra
of the model rats (group B) showed no difference with
the rats administered Ipt, Dia or L-dopa respectively,
although they were significantly higher than that of
the vehicle control rats (group A). The mRNA levels
in both brain regions also showed no difference
among each group (data not shown).
Discussion
Rotenone induced depletion of ATP and over-
production of reactive oxide species (ROS) by inhibit-
ing CXI. The toxicity of rotenone in the nigro-striatal
dopaminergic system depends on the drug regimen
because acute, high doses are toxic to virtually any
cell of an organism, but a low dose given chronically
can be tolerated by most cells, except dopaminergic
neurons (Alam and Schmidt, 2002 ; Betarbet et al.,
2000 ; Fahn and Przedborski, 2000 ; Ferrante et al.,
1997 ; Sherer et al., 2003). In the present study, rats
were chronically administered 2.5 mg/kg . d rotenone
for 4 wk and exhibited Parkinsonian symptoms.
Accompanying a 60% decrease in striatal DA levels,
the ratios of DOPAC/DA and HVA/DA increased.
These results suggest an increased turnover and
release of DA as a compensatory mechanism in sur-
viving neurons exists after partial injury of the nigro-
striatal system (Hsieh et al., 2002 ; Thiffault et al., 2000).
Compared to normal rats, rotenone-treated rats
displayed an increase in cataleptic behaviour and a
decrease in locomotor activity, which could be re-
versed by administration of L-dopa, also supporting
the view that rotenone-induced neurodegeneration
Table 3. Effects of iptakalim, diazoxide and L-dopa on monoamine levels in the substantia nigra of rotenone-treated rats
Groups (mg/kg) DA DOPAC HVA NE 5-HT 5-HIAA
(A) Veh+Sal 372¡34 151¡28 74¡7 149¡14 502¡40 539¡74
(B) Rot+Sal 199¡28** 102¡19** 40¡7** 81¡14** 355¡67** 404¡56**
(C) Rot+Ipt 0.75 260¡30**## 137¡23## 52¡6**## 104¡12**## 415¡7* 438¡64*
(D) Rot+Ipt 1.5 312¡28## 153¡23## 64¡9## 134¡19## 467¡65## 496¡46##
(E) Rot+Ipt 3.0 347¡28## 163¡11## 69¡6## 139¡11## 486¡39## 500¡25##
(F) Rot+L-dopa 10 281¡63**## 198¡25**## 76¡8## 152¡16## 362¡62** 390¡66**
(G) Rot+Dia 3.0 376¡61## 159¡23## 71¡10## 142¡21## 467¡54## 496¡46##
(H) Rot+5-HD 5.0+Ipt 3.0 238¡25**#++ 104¡22**++ 48¡5**++ 95¡10**++ 400¡40**++ 418¡40**++
(I) Rot+5-HD 5.0+Dia 3.0 212¡31**## 110¡36*## 42¡6**## 84¡12**## 370¡47**## 384¡38**##
DA, Dopamine; DOPAC, dihydroxyphenylacetic acid ; HVA, homovanillic acid ; NE, noradrenalin ; 5-HT, serotonin ; 5-HIAA,
5-hydroxyindoleacetic acid ; Veh, vehicle ; Sal, saline ; Rot, rotenone ; Ipt, iptakalim; Dia, diazoxide ; 5-HD, 5-hydroxydecanoate.
Data are expressed as picograms per milligram (pg/mg) of fresh brain weight and given as mean¡S.E.M. (n=8). p represents
statistical analysis : * p<0.05, ** p<0.01 vs. group A; # p<0.05, ## p<0.01 vs. group B; +p<0.05, ++p<0.01 vs. group E;
# p<0.05, ## p<0.01 vs. group G (one-way ANOVA followed by the Newman–Keuls test).
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in rats represents a valid animal model of PD (Alam
and Schmidt, 2002, 2004).
Interestingly, Dia and Ipt could also improve the
behavioural alterations and restored DA deletion
in the nigro-striatal system of rotenone-treated rats,
which could be abolished by pretreatment with 5-HD,
a selective mito-KATP channel blocker. As a result,
it is clear that activation of mito-KATP channels was
involved in the neurorestorative effects of Dia and
Ipt. The exact mechanism of how mito-KATP channels
are involved in neuroprotection and neurorestoration
remains unknown. We supposed that dopaminergic
neurons and glial mechanisms were both involved
in the neurorestorative effects produced by mito-KATP
channel activation.
First, in the rotenone model, the free toxin concen-
tration is in the range of 20–30 nM. This corresponds
to the degree of CXI inhibition found in PD (Schapira
et al., 1998) but might not substantially impair ATP
synthesis in brain mitochondria. Liss believed that
the sKATP channel is differentially expressed in dopa-
minergic neurons and directly senses CXI inhibition.
It is, however, sufficient to activate SUR1/Kir6.2-
containing sKATP channels in dopaminergic neurons.
The protection afforded by sKATP activation is largely
due to energy preservation and reduction of Ca2+
influx (Yamada et al., 2001), while excessive opening
of sKATP channels in neurons may have deleterious
consequences : resulting in chronic hyperpolarization
and reduction of excitability, reducing expression of
activity-dependent genes that promote survival, such
as neurotrophins and causing fatal consequences
for the dopaminergic neuron (Liss and Roeper, 2001 ;
Yamada et al., 2001). Moreover, recent studies in-
dicated that NO played an important role in rotenone-
induced selective nigro-striatal neurodegeneration
(Bashkatova et al., 2004 ; He et al., 2003). NO can
inhibit mitochondrial complexes I, II, and IV in the
respiratory chain, activate or initiate DNA strand
breakage, lipid peroxidation and protein oxidation
by increasing the generation of toxic radicals such
as hydroxyl radicals and peroxynitrite (Brown and
Borutaite, 2002 ; Ebadi and Sharma, 2003). Peroxy-
nitrite could deactivate tyrosine hydroxylase, the
initial and rate-limiting enzyme in the biosynthesis
of DA (Ara et al., 1998 ; Beckman et al., 1993 ;
Blanchard-Fillion et al., 2001). Therefore, the injury
and inactivation of tyrosine hydroxylase caused by
dopaminergic neurons may be responsible for the
decline in DA synthesis and release (Abreu et al.,
2000 ; Ischiropoulos et al., 1995). All these events have
been postulated to be involved in PD. Previous
studies suggested that low doses of rotenone induced
apoptosis instead of necrosis in dopaminergic neurons
(Fiskum et al., 2003 ; Greenamyre et al., 1999). This
should be the result of chronic sKATP activity of
dopaminergic neurons and the attack of NO. We also
found that the behavioural dysfunction of the model
rats without any treatment became worse although
rotenone withdrew, which also supported the view
that apoptosis occurred (Table 1). So rats treated with
2.5 mg/kg . d rotenone for 4 wk in our study mimic
early PD.
Under the physiological conditions, mito-KATP
channel openers could not only preserve mito-
chondrial function by regulating intracellular signal
transduction, mitochondrial volume and calcium
homeostasis, but also exert anti-apoptotic effects
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Figure 2. iNOS activity in the striatum (a) and substantia
nigra (b). Data are presented as mean¡ S.E.M. (n=5).
p represents statistical analysis : * p<0.01 vs. lane A;
# p<0.01 vs. lane B; + p<0.01 vs. lane E ; # p<0.01 vs. lane G
(one-way ANOVA followed by the Newman–Keuls test).
Lane A, vehicle control rats+0.2% DMSO in saline (p.o.) ;
lane B, rotenone model rats+0.2% DMSO in saline (p.o.) ;
lane C, rotenone model rats+0.75 mg/kg . d Ipt (p.o.) ; lane
D, rotenone model rats+1.5 mg/kg . d Ipt (p.o.) ; lane E,
rotenone model rats+3.0 mg/kg . d Ipt (p.o.) ; lane F,
rotenone model rats+10 mg/kg . d L-dopa (p.o.) ;
lane G, rotenonemodel rats+3.0 mg/kg . d Dia (p.o.) ; lane H,
rotenone model rats+5.0 mg/kg . d 5-HD+3.0 mg/kg . d Ipt
(p.o.) ; lane I, rotenone model rats+5.0 mg/kg . d
5-HD+3.0 mg/kg . d Dia (p.o.).
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by affecting cytochrome c release and caspase acti-
vation and translocation of apoptosis-related cytosolic
Bax to mitochondria (Busija et al., 2004 ; Horiguchi
et al., 2003 ; Kis et al., 2003 ; Liu et al., 2002 ; Mattson
and Liu, 2003 ; Rajapakse et al., 2002; Teshima et al.,
2003). We, therefore, supposed that Ipt and Dia
might restore the sick dopaminergic neurons and
preserve DA synthesis and release, thereby improving
the behavioural dysfunction by opening mito-KATP
channels although further study needs to be done to
investigate the exact mechanism.
Was there a non-dopaminergic neuron mechanism
underlining the protections of mito-KATP openers? In
this study, there was a robust increase in both NOS
activity (including iNOS and nNOS) and iNOS mRNA
levels in the striatum and substantia nigra of rats
challenged with rotenone, which were associated
with behavioural abnormalities and decrease of DA
contents in those regions respectively. The increase
of iNOS activities might be due to the elevated
mRNA levels. Interestingly, Ipt and Dia reduced
the activity of iNOS, but had no effect on the elevated
activity of nNOS (data not shown) after chronic
rotenone treatment, suggesting that NO from iNOS
expressed in glial cells appears to be a key mediator
of rotenone-induced neuronal death. Similar results
were also found in previous studies (Brown and Bal-
Price, 2003 ; Sparrow, 1994–1995). The results sug-
gested that mito-KATP channels of glial cells might
be another important target for the restorative effect
of Ipt and Dia against rotenone toxicity. We also be-
lieved that mito-KATP openers exert similar restorative
effects on other neurons in the brain challenged by
rotenone. However, the endogenous mechanism of
how mito-KATP channels regulate iNOS mRNA levels
is unknown. Further work needs to be done to address
whether selective iNOS inhibitors can exert protective
effects against rotenone-induced neuronal injury
in rats and decide the exact function of mito-KATP
channels in glial cells.
In this study, we demonstrate, for the first time,
that rotenone-induced Parkinsonian symptoms (e.g.
catalepsy) in rats are reversed by Ipt and Dia, and
that mito-KATP channel openers may therapeutically
be used for early PD. The regulation of dopaminergic
neurons apoptosis and glial iNOS activity might
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Figure 3. iNOS mRNA levels in the striatum (a) and substantia nigra (b). Data are presented as mean¡ S.E.M. (n=5). p represents
statistical analysis : * p<0.01 vs. lane A; # p<0.01 vs. lane B; + p<0.01 vs. lane E; # p<0.01 vs. lane G (one-way ANOVA
followed by the Newman–Keuls test). Lane A, vehicle control rats+0.2% DMSO in saline (p.o.) ; lane B, rotenone model
rats+0.2% DMSO in saline (p.o.) ; lane C, rotenone model rats+0.75 mg/kg . d Ipt (p.o.) ; lane D, rotenone model
rats+1.5 mg/kg . d Ipt (p.o.) ; lane E, rotenone model rats+3.0 mg/kg . d Ipt (p.o.) ; lane F, rotenone model rats+10 mg/kg . d
L-dopa (p.o.) ; lane G, rotenone model rats+3.0 mg/kg . d Dia (p.o.) ; lane H, rotenone model rats+5.0 mg/kg . d
5-HD+3.0 mg/kg . d Ipt (p.o.) ; lane I, rotenone model rats+5.0 mg/kg . d 5-HD+3.0 mg/kg . d Dia (p.o.).
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be a neurorestorative target of mito-KATP channel
openers against rotenone toxicity.
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